Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol dose-reduction and withdrawal maintenance study in axial spondyloarthritis
NL-OMON44938Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Jan 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS) (4 arms), sponsored by UCB. Started Jan 2016; status: active, not recruiting.
02
Drugs
certolizumab pegol
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON44938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44938.